Get the Stockscreener App
0.33
8.10%
-0.0291
Bioatla Inc stock is traded at $0.33, with a volume of 491.29K.
It is down -8.10% in the last 24 hours and down -15.49% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.3591
Open:
$0.3549
24h Volume:
491.29K
Relative Volume:
0.80
Market Cap:
$19.28M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1274
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
-6.99%
1M Performance:
-15.49%
6M Performance:
-29.79%
1Y Performance:
-81.14%
1-Day Range:
$0.3255
$0.3591
1-Week Range:
$0.3255
$0.385
52-Week Range:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.33 | 20.98M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
Published on: 2025-08-02 01:56:13 - Newser
Trading Bots Trigger Alerts on BioAtla Inc. ActivityHigh Accuracy Alerts for ROI Traders Detected - metal.it
Is BioAtla Inc. still worth holding after the dipExpert-Backed High Yield Stock Watchlist - Newser
What is the dividend policy of BioAtla Inc. stockEarnings Report Outlook For 2025 - jammulinksnews.com
How volatile is BioAtla Inc. stock compared to the marketPre Market Picks With High Returns - jammulinksnews.com
Is it the right time to buy BioAtla Inc. stockRetirement Planning Forecasts Backed By Experts - jammulinksnews.com
How does BioAtla Inc. generate profit in a changing economyDaily Trading Report For Consistent Profits - jammulinksnews.com
Why BioAtla Inc. is moving todayFundamental Forecast for Undervalued Stocks - Newser
Buy Signal for BioAtla Inc. Stock Key Technical Indicators to WatchFree Risk Controlled Short Term Trade Plans - Newser
How sentiment analysis helps forecast BioAtla Inc.Free Trade Ready Stock Watch for Short Term - Newser
Why BioAtla Inc. stock attracts strong analyst attentionConservative Investment Setup and Risk Analysis - Newser
What are the technical indicators suggesting about BioAtla Inc.Stock Strategy Review That Work - jammulinksnews.com
Can volume confirm reversal in BioAtla Inc.Weekly Stock Market Strategy Summary - Newser
Automated trading signals detected on BioAtla Inc.Free Consistent Income Focused Trade List - Newser
BioAtla (NASDAQ:BCAB) Stock Price Down 1.8% – Should You Sell? - Defense World
BioAtla Inc. Enters Reversal Setup in Weekly ChartsTriple Return Setup With Risk Control Explained - beatles.ru
Technical Bounce Expected in BioAtla Inc. Next WeekConsistent Profit Pattern Recognition Tools Shared - metal.it
BioAtla Inc. Stock Performance After Earnings: Historical InsightsLong-Term Growth Trend Summary With Confidence - Newser
What analysts say about BioAtla Inc. stock outlookMulti-Bagger Detection with Trend Tools - Newser
Top Risks to Consider Before Buying BioAtla Inc. StockDaily Market Momentum and Pressure Analysis - Newser
BioAtla Inc. Reaches Critical Trendline SupportNews Based Entry Opportunity Alerts Detected - metal.it
Moving Average Crossover Confirms Uptrend in BioAtla Inc.AI Powered High Return Stock Calls Dominate Watchlists - metal.it
Is BioAtla Inc. a growth stock or a value stockPre Market Picks With High Returns - jammulinksnews.com
What is the risk reward ratio of investing in BioAtla Inc. stockLow Risk Watchlist With High Returns - jammulinksnews.com
Is BioAtla Inc. still worth holding after the dip High Probability Trade Outcome Prediction - Newser
Does BioAtla Inc. stock perform well during market downturnsTriple-digit profit margins - jammulinksnews.com
Should I hold or sell BioAtla Inc. stock in 2025Free Stock Market Forecast Reports - jammulinksnews.com
What makes BioAtla Inc. stock price move sharply Capital Protection Strategy With Risk Analysis - Newser
What makes BioAtla Inc. stock price move sharplyProfitable Yet Secure Picks - Newser
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):